Table 1.
Group | Leading institutions | Consortium activities (beyond data sharing) |
---|---|---|
ORIEN2 | The Moffitt and The Ohio State University Comprehensive Cancer Centers | Biobank and investigational drugs procurement |
MED‐C3 | Molecular Evidence Development Consortium | Reimbursement for tumor sequencing |
TAPUR4 | The American Society of Clinical Oncology | Availability of targeted therapy off label |
APOLLO5 | National Cancer Institute, Department of Veterans Affairs and the Department of Defense | Tissue and data for biomarker development (proteogenomics) |